CG Products Bucket

  1. Compact Aseptic Processing Isolator System: CAP-IS 7/4/2026

    CAP-IS (Compact Aseptic Processing Isolator System) is a cGMP Class A/ISO 5 isolation system, specifically designed for pharmaceutical production laboratories.

  2. AP-IS Series: Aseptic Processing Isolator Systems 7/2/2026

    The Aseptic Filling Isolator is a custom-designed cGMP Class A/ISO 5 isolator system specifically designed for batch scale pharmaceutical production of injectable products for pre-clinical and clinical trial studies.

  3. Automatic Glove Leak Tester 7/1/2026

    AGLTS 2 is the brand new fully automatic GMP compliant Glove Leak Tester for Pharmaceutical Isolators and RABS in the pharmaceutical industry, developed referring to the Positive Pressure Decay Method which follows the international standard ISO 14644-7 Annex E.5.

  4. Automatic Integrity Tester For Alpha And Beta Rapid Transfer Systems 6/30/2026

    ZEROC is the new RTP tester developed to perform a complete integrity test on Rapid Transfer Ports (Alpha part), installed on isolators or RABS, and their containers (Beta part) in a fully automatic way.

  5. Accelerate Your Next In Vivo CAR-T Program 6/1/2026

    Explore how Lonza supports complex in vivo modalities with scalable manufacturing solutions, advanced analytics, and end to end CMC expertise across viral vector and RNA LNP platforms, from early development through clinical readiness.

  6. Support For Efficient FDA Interactions 5/27/2026

    In today’s regulatory climate, ongoing discussion about FDA workload, funding constraints, and shifting review priorities have sparked anxiety across the biopharma industry — especially for sponsors preparing for key submissions like INDs or NDAs. At Veristat, our most recent interactions reflect continued responsiveness and constructive engagement from FDA.

  7. Increase Cell Culture Yield Without Increasing Aggregation 5/22/2026

    Designed for CHO cell culture processes, the HyClone™ glycan supplement enhances galactosylation and maintains stable culture performance.

  8. Your Strategic Partner With A Global Network Of Support 5/20/2026

    With ParexelAI™, you're not just optimizing your current development timeline, you're unlocking the ability to run more programs simultaneously across our global network and compress critical timelines. In a landscape where speed to market directly impacts patient outcomes, ParexelAI empowers you to innovate and make a meaningful difference in patients' lives.

  9. Portfolio Optimization Strategic Consulting 5/5/2026

    For each prospective compound, we help you think through its clinical implications, safety parameters, and side effects to establish what will differentiate it in the current market landscape. With multiple drugs and limited funds, you need to choose the right products early. These best prospects will then generate cash and asset value to develop others.

    In partnership with Health Advances, we’ll help you decide which investments will get you to an early proof of concept, which assets to advance and which to hold back, and which assets have synergies with others, whether in production, use, or market position. By the end of it all, you’ll have an effective, fully optimized portfolio.

  10. iPSC Drug Discovery Platform 5/1/2026

    An iPSC drug discovery platform delivering end‑to‑end genome engineering, differentiation, and GMP transition to generate biologically relevant human cell models for efficient discovery and translation.